I was unaware that the result from Lilly was not the only recent major failure of a clinical trial of antibodies to the amyloid plaques in the brains of Alzheimer’s patients. It seems that many other big and little-name drug companies have been trying the same approach with their dozen or so different antibodies. Each is trying to make it to market first where the biggest money lies. (Consumers should beware when the commercial pressures are this great.)
Last month, Pfizer and its partners announced a similar failure of several studies which showed no clinical improvement when their particular antibody, bapineuzumab, was administered to several thousand patients over 18 months. Continue reading “More Failed Studies of Antibody Treatment for Alzheimer’s Disease.”